MAP’s vision is to be the market leader in accelerating patient access to medicines, devices and diagnostics. MAP’s Online platform is your one-stop market access portal, which you can rely on for consistent advice and support. MAP Online and the support team can help your organisation to make the right decisions on market access strategy, reducing time and costs. MAP Online supports you throughout the entire market access process, supplementing consulting requirements and ensuring you always have the right resources and knowledge.
The past year has seen significant changes in the landscape for biosimilars, with the EU’s adoption of changes to regulations around biosimilar manufacturing and launch, and the expiration of the EU patent on the world’s biggest-selling drug adalimumab.
MAP’s consulting services and MAP Online, our online knowledge portal, provide our members with information and expert insights into the latest developments for market access in the UK and EU5, from EMA regulatory considerations, to the Health Technology Assessment options available to biosimilars, to contracting and tendering processes, as well as overall launch strategy and planning.
With a membership to MAP Online you will have access to our extensive database with a wealth of time saving materials as well as access to our highly experienced market access, health economics, policy & public affairs and legal consultants.
- Funding flows
- Routes to reimbursement
- Early access options
- Stakeholder engagement strategies
Tools and resources
- ICER calculator
- Budget impact model
- International Reference pricing tracker
- HTA database statistics and trends
- Training materials and presentations
- Articles on latest topics and trends